{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:30:31Z","timestamp":1789684231235,"version":"4.0.1"},"reference-count":0,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropediatrics"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Opsoclonus-myoclonus syndrome (OMS) is a neuroinflammatory disorder with pervasive morbidity that warrants better treatments. Twelve children with moderate\/severe OMS (total score 23\u2009\u00b1\u20096) who did not remit to multiple immunotherapies were evaluated for neuroinflammation in a case\u2013control study using cerebrospinal fluid (CSF) lymphocyte subset analysis by flow cytometry, chemokine\/cytokine analysis by enzyme-linked immunoadsorption assay (ELISA), and oligoclonal bands by immunofixation with isoelectric focusing. Observations made on empirical treatment with rituximab, IVIg, and tetracosactide combination immunotherapy (coined \u201cRITE-CI\u201d) were analyzed. All of the patients tested for multiple inflammatory markers were positive; 75% had \u22653 CSF markers. Fifty percent had CSF oligoclonal bands; 58%, B cell expansion; and 50 to 100%, elevated concentrations of multiple chemokines and neuronal\/axonal marker neurofilament light chain. After RITE-CI, total score dropped significantly in the group (\u221285%, p\u2009&lt;\u20090.0001) from moderate to trace, and by 2 to 4 severity categories in each patient. The 24-week schedule was well tolerated and clinically effective for moderate or severe OMS, as were other schedules. RITE-CI is feasible and effective as rescue therapy and presents an initial option for children with moderate\/severe OMS. Though preliminary, the schedule can be adjusted to patient severity, propensity for relapse, and other factors.<\/jats:p>","DOI":"10.1055\/s-0037-1609038","type":"journal-article","created":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T18:49:28Z","timestamp":1513709368000},"page":"123-134","source":"Crossref","is-referenced-by-count":9,"title":["Rituximab, IVIg, and Tetracosactide (ACTH1\u201324) Combination Immunotherapy (\u201cRITE-CI\u201d) for Pediatric Opsoclonus-Myoclonus Syndrome: Immunomarkers and Clinical Observations"],"prefix":"10.1055","volume":"49","author":[{"given":"Elizabeth","family":"Tate","sequence":"first","affiliation":[{"name":"National Pediatric Myoclonus Center and National Pediatric Neuroinflammation Organization, Inc., Orlando, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Alber","sequence":"first","affiliation":[{"name":"Department of Neuropaediatrics, Developmental Neurology, Social Paediatrics, University Children's Hospital T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Awadalla","sequence":"first","affiliation":[{"name":"Pediatric Neurology Unit, Dr. Erfan and Bagedo General Hospital, Jeddah, Kingdom of Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubov","family":"Blumkin","sequence":"first","affiliation":[{"name":"Pediatric Neurology Unit, Wolfson Medical Center, Holon, Sackler School of Medicine, Tel-Aviv University, Holon, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Lina","sequence":"first","affiliation":[{"name":"Department of Psychoneurology No. 2, Federal State Medical Institution, Russian Children's Clinical Hospital, Ministry of Health Russian Federation, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Leiz","sequence":"first","affiliation":[{"name":"Pediatric Neurology Unit, Department of Pediatrics and Adolescent Medicine, Hospital Dritter Orden, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"M\u00f3ser","sequence":"first","affiliation":[{"name":"Department of Neurology, Heim Pal Children's Hospital, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pranzatelli","sequence":"additional","affiliation":[{"name":"National Pediatric Myoclonus Center and National Pediatric Neuroinflammation Organization, Inc., Orlando, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2017,12,19]]},"container-title":["Neuropediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0037-1609038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T19:43:13Z","timestamp":1521229393000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0037-1609038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,19]]},"references-count":0,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2018,3,16]]},"published-print":{"date-parts":[[2018,4]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0037-1609038","relation":{},"ISSN":["0174-304X","1439-1899"],"issn-type":[{"value":"0174-304X","type":"print"},{"value":"1439-1899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,19]]}}}